Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
![PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/72ce80f2da87d037624955a597846d530a0c6052/3-Figure1-1.png "PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar")
PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar
International Clinical Cytometry Society
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Cureus | CD38: From Positive to Negative Expression after Daratumumab Treatment | Article
Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action - Adams - 2019 - Cytometry Part A - Wiley Online Library
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar
International Clinical Cytometry Society
KoreaMed Synapse
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance | Semantic Scholar
ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines
A Guide to Plasma Cell Markers | Biocompare: The Buyer's Guide for Life Scientists
Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells | PLOS ONE
CD38, A Target for Immunotherapeutic Approaches in Cancer
In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma | Journal of Hematology & Oncology | Full Text
Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems
Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
CD38 - Wikipedia
Double CD38−/CD138− negative multiple myeloma - ScienceDirect
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
Expression of CD38 in normal and malignant plasma cells.... | Download Scientific Diagram
Cells | Free Full-Text | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
